Street Calls of the Week
LAS VEGAS - Hypha Labs, Inc. (OTCQB:FUNI), a micro-cap biotechnology company currently valued at $3.85 million and trading below its InvestingPro Fair Value, has entered an agreement with Automated Technical Services to design and build a commercial-scale Mushroom Accelerator, the company announced Monday.
The new system will produce Hypha’s proprietary mushroom-based ingredients for sale to nutraceutical manufacturers globally, scaling up from the company’s current countertop units that compress the production of functional mushroom compounds from months to eight days.
The collaboration aims to expand Hypha’s production capabilities to serve the functional mushroom market, which the company states is valued at $33 billion globally and projected to reach $49 billion by 2028. According to InvestingPro analysis, the company faces significant financial challenges with a weak financial health score of 1.42 and a current ratio of 0.16, indicating potential liquidity concerns.
Under the agreement, ATS will work with Hypha’s R&D team to adapt the company’s proprietary processes to a commercial production environment, enabling supply to nutraceutical brands and supplement manufacturers.
"This agreement is a major step in taking our Mushroom Accelerator technology from the kitchen counter to industrial production," said Craig Ellins, Chief Scientific Officer of Hypha Labs, in the press release statement.
Hypha Labs is currently conducting a Regulation A+ public offering for investors interested in the company’s expansion from consumer devices to large-scale ingredient production.
The company describes its technology as a method for producing active ingredients found in functional mushrooms using patent-pending mushroom accelerators.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.